News, Deals & Cases

On 22 July 2021, SOPHiA GENETICS SA, a Swiss healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research, priced its USD 234 million IPO, consisting of an offering of 13,000,000 ordinary shares at a price of USD 18.00 per share. The ordinary shares…

End of July 2021, Idorsia Ltd successfully placed CHF 600 million senior unsecured convertible bonds due 2028 in a private placement with institutional investors. The net proceeds of the convertible bonds will be used to support commercial product launches in several key markets and to fund the further development of the company’s advancing late-stage pipeline….

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, on 27 July 2021 announced that it is acquiring Affiris SA’s portfolio of therapeutics targeting alpha-synuclein (a-syn) as well as cash for 7.1 million shares based on a price of USD 8.26 per common share of AC Immune. The acquisition…

On 9 April 2021, VectivBio Holding AG announced its initial public offering and listing of its shares on Nasdaq (ticker symbol VECT). VectivBio is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Through its IPO,…

On 22 April 2021 Credit Suisse Group AG announced the placement of two series of Mandatory Convertible Notes (CHF 865,000,000 3.00 per cent. Series A Mandatory Convertible Notes due 2021 (Series A) and CHF 890,949,000 3.00 per cent. Series B Mandatory Convertible Notes due 2021 (Series B)), issued through a Guernsey finance vehicle and convertible…

On 29 April 2021, PolyPeptide Group commenced trading on SIX Swiss Exchange. The offering consisted of 3,125,000 new shares as well as 8,396,740 existing shares offered by PolyPeptide’s sole shareholder, Draupnir Holding B.V., at an offer price of CHF 64.00 per share (with an over-allotment option of up to 1,728,261 existing shares), which implies a…

On 4 May 2021, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced the settlement of the first exchange offer for a convertible bond in Switzerland. Holders of Santhera’s existing CHF 60 m Senior Unsecured Convertible Bonds due 2022 received one new CHF 30,270,375 Senior Unsecured Convertible Bond due 2024 and 26 Santhera shares per existing bond….

On 10 May 2021, Credit Suisse Group AG launched, and on 14 May 2021, successfully completed, the issuance of USD 3.25bn 3.091% Fixed Rate/Floating Rate Senior Callable Notes due 2032 under its U.S. Senior Debt Program. The Notes are bail-inable bonds that are eligible to count towards Credit Suisse’s Swiss gone concern requirement. The offering…